Home » Prescription Drugs 5 » D Penamine Cuprimine
Indications:Severe active rheumatoid arthritis.As a chelating agent in the treatment of Wilson's disease and lead poisoning. D-Penamine will enhance the urinary excretion of gold and mercury and other heavy metals.In the treatment of cystinuria in cases where high-fluid regimens are not adequate or in conjunction with them.Dosage and Administration:D-PENAMINE is intended for oral administration in adults. In all patients receiving D-penicillamine it is important that D-PENAMINE be given on an empty stomach at least one hour before meals or two hours after meals and at least one hour apart from any other drug food or milk.Rheumatoid DiseaseNot more than 250 mg daily for one month increasing by the same amount at intervals of not less than one month until a daily dose of 1500 mg has been reached. The dose should be kept to the lowest which is effective in order to minimise side-effects. Many patients respond to a maintenance dose of 750 mg daily and it may be worthwhile to keep patients on this dosage for several months before deciding on a further increment. There is no pre-determined dose of D-PENAMINE which will suit all patients and the dose for each individual must be sought by careful monitoring over a period of months. D-penicillamine should be given in divided doses. Therapeutic response to changes in maintenance dosage usually will not become evident for six to eight weeks. Some do not respond despite continued use of full doses. There is little point in persevering with D-PENAMINE if there is no response after six months at a full maintenance dose. Occasionally patients who have responded initially to a particular dose begin to relapse. Most of these will respond to an increase which should be gradual. Both seronegative and seropositive rheumatoid arthritis usually respond to D-PENAMINE.As a Chelating AgentWilson's diseaseMost adult patients require the medicine in a daily dose of 1500 mg to 2000 mg. Improvement is often slow though cupruresis is immediate and there may be clinical deterioration at first. Except in the most advanced case substantial improvement can generally be expected. Patients who are vomiting or unable to swallow should be given parenteral E.D.T.A.Lead PoisoningPatients who are vomiting or who are unable to swallow should be given parenteral E.D.T.A. but all others are best treated by means of D-PENAMINE in an oral dose of 250 to 1000 mg daily in divided doses.Other heavy metals poisoningD-PENAMINE will enhance the urinary excretion of gold iron antimony zinc and mercury.CystinuriaA single 500 mg dose on retiring following free fluids during the day may effect stone dissolution in a functioning kidney. 750 to 1000 mg daily in divided doses is generally adequate and it should not be necessary to exceed 2000 mg daily.ChildrenD-PENAMINE is not recommended for use in children.
Buy D Penamine Cuprimine and other Prescription Drugs 5 products online
at Medstore.
789 Buy Online at Medstore - Click Here!

About D Penamine Cuprimine:
Product Type: Prescription Drugs 5
D-Penamine ( Cuprimine Depen Generic D-Penicillamine )
D-Penamine (Cuprimine Depen Generic D-Penicillamine)
Cuprimine Depen Generic D-Penicillamine
125mg 100 Tablets 250mg
Cuprimine Depen Generic D-Penicillamine D-Penamine

View more
Prescription Drugs 5
Previous Product Next Product
Online Prescriptions.
Industry News : Marquette General Health System joins Premier healthcare alliance. Marquette General Health System of Marquette, Mich., has joined the Premier healthcare alliance, consisting of more than 2,500 hospitals and 76,000 other healthcare sites, to improve care delivery.
“We believe this new partnership will help improve the value of the health services Marquette provides to our community and look forward to furthering our work with Premier.”
As a Premier owner, Marquette leverages a national purchasing network delivering industry-leading contract pricing. The not-for-profit health system formerly utilized MedAssets as its national purchasing organization.
Marquette also collaborates and compares performance with other members of the alliance to improve care efficiency while safely reducing waste and costs using the nation's largest clinical, financial and operational database.
"Premier's business model is unique in that it is completely owned by its members and thus accountable to and fully aligned with their goals," said Gary Muller, president & CEO at Marquette. "We believe this new partnership will help improve the value of the health services Marquette provides to our community and look forward to furthering our work with Premier."
The health system participates in two Premier collaboratives for additional performance improvement opportunities.
As a new member of Premier's ASCEND® (Accelerated Supply Chain Endeavor) program, Marquette aggregates, monitors and analyzes supply chain data to identify improvement opportunities. This includes simplified and consistent purchasing processes, appropriate clinical utilization and specially negotiated contracts. Members of ASCEND have saved $56 million over two years, without sacrificing the quality of care.
To support its purchasing decisions, the health system uses Premier supply chain tools like SpendAdvisor® MySpend™, to easily examine spend data.
MACLAR Klacid
Macrobid (Nitrofurantoin)
Macrodantin (Nitrofurantoin Macrocystals)
MADOPAR Prolopa
Malirid Generic Primaquine
Marvelon Desogestrel Ethinyl Oestradiol
Maxalt (Rizatriptan)
Maximune Invirase
Maxolon Clopra
Maxolon (Metoclopramide)
MEBEX Vermox
Medrol Deltastab
MEFTAL Ponstel
Melalite Forte Cream Aclaro
Melanocyl Uvadex
MELOSET MEL
Memantine NAMENDA
M Enalapril Generic Renitec
Meprate Modus
MESACOL Asacol
Metaspray Nasonex
Metformin Generic Glucophage
Methotrexate
Methycobal Generic Mecobalamin
Metocard XL Toprol XR
METOLAR Betaloc
METOLAR H Selopres
Metpamid Reglan


|